Hematopathologic Correlates of CAR T-Cell Therapy

Area of Science:

• Immunotherapy
• Hematologic Oncology
• Cellular Therapy

Background:

• CD19-targeting chimeric antigen receptor (CAR) T-cell therapies are established treatments for relapsed/refractory B-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma.
• The clinical success of CD19-CAR T-cells fuels research into CAR T-cell products targeting alternative antigens for broader applications in hematologic malignancies and solid tumors.

Purpose of the Study:

• To highlight the critical role of clinical laboratories in the manufacturing, distribution, and patient monitoring processes of CAR T-cell therapy.
• To emphasize the necessity for laboratory professionals to possess a strong understanding of the clinicopathologic aspects associated with CAR T-cell therapy.

Main Methods:

• Review of current literature on CAR T-cell therapy applications and manufacturing processes.
• Analysis of the clinical laboratory's involvement in the CAR T-cell therapy workflow.

Main Results:

• CD19-CAR T-cell therapy is effective for specific B-cell malignancies.
• Expanding research targets novel antigens for CAR T-cell therapy in diverse cancers.
• Clinical laboratories are integral to the successful implementation and oversight of CAR T-cell therapy.

Conclusions:

• Laboratory professionals require comprehensive knowledge of CAR T-cell therapy to ensure patient safety and treatment efficacy.
• Understanding the clinicopathologic landscape is essential for laboratory personnel involved in CAR T-cell therapy.